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Small-diameter vascular grafts face implantation problems such as thrombosis, increased rate of 
infection, chronic inflammatory responses and compliance mismatch between the native tissue and 
the prosthetic material. It has been hypothesized that a fully-endothelialized lumen would enhance 
biocompatibility and improve graft patency. This could be done by introducing either 
topographical or biochemical cues to the graft. In this study, two types of polymers were used; the 
polysaccharides pullulan and dextran, and a synthetic polymer, poly(vinyl alcohol) (PVA). Both 
material types were previously characterized as potential graft materials by Chaouat et al., in 
which they demonstrated short-term graft patency, although both materials were relatively inert 
and did not facilitate vascular tissue regeneration. The incorporation of poly-electrolyte 
complexation (PEC) fibers, which are known to be able to perform sustained release of various 
biologics, with the polysaccharide and PVA materials respectively have improved the scaffolds’ 
abilities to perform a sustained release of proteins. PVA-PEC fiber composites further showed that 
mechanical strength was enhanced compared to PVA-only scaffolds. Finally, a novel method of 
solvent casting with PVA was developed, allowing micro- and nanometer-sized gratings to be 
fabricated on the surface of PVA films. Further in-vitro endothelial cell adhesion studies 
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1.1 Clinical Problem - Peripheral Artery Disease 
Peripheral artery disease (PAD) is a type of vascular disease, categorized with disease conditions 
such as carotid artery, renal artery and aortic disease. PAD occurs when the arteries in the 
extremities, most often in the legs, experience plaque buildup within the vessel intima. Although 
how this happens is still unclear, the “response-to-injury” theory has been widely accepted as a 
probable mechanism. Endothelial injury occurs from a range of factors; oxidized low-density 
lipoprotein, infectious agents, toxins such as those incurred from smoking, hyperglycemia and 
hyper-homocystinemia. Injury typically leads to vascular inflammation and a fibro-proliferative 
response. Circulating monocytes enter the damaged intima and remain there, taking up low density 
lipoprotein cholesterol, eventually forming foam cells characteristic of early atherosclerosis. This 
buildup and plaque formation leads to vascular remodeling, abnormalities of blood flow and 
reduced oxygen supply to target organs [1]. 
 
PAD affects 12 to 20 percent of Americans over 65 years of age, with only 25 percent of PAD 
patients undergoing treatment [2]. In Singapore, peripheral artery disease is a major cause of limb 
loss [3]. It is especially prevalent in patients with diabetes, with a study in 2004 revealing that 
about 20% of diabetic patients over 60 years of age possess a positive history for claudication, 
gangrene or non-traumatic amputation as a result of PAD [4]. Although PAD can be diagnosed 
through symptoms such as sensations of intermittent claudication and weak systolic pressure in the 
limbs, a majority of PAD patients are asymptomatic or have variable non-classic PAD symptoms 
[2], causing pronounced difficulty in early diagnosis and prevention of the disease. For example, 
in Singapore, over 50% of diagnosed PAD patients are asymptomatic, while in America only an 




Surgical bypass of occluded arterial segments had been the mainstream choice of surgical 
treatment in the previous decade. Use of autologous veins derived from the patient remains as the 
gold standard for vascular grafts in bypass surgery. Unfortunately, autologous graft sources are 
scarce as autologous veins are not available or inadequate in a large number of patients due to 
coexisting vascular diseases or previous vessel utilisation. While synthetic grafts have been used 
with success in large diameter arteries, considerable difficulties have been met in developing 
small-diameter arterial grafts with long-term patency rates. 
 
1.2 Hypothesis 
In this study, it is hypothesized that the incorporation of poly-electrolyte complexation fibers into 
the scaffold will enable the scaffold to release biologics at a controlled and sustained rate. 
The modification of the surface topography will improve cell attachment and hence patency of the 
scaffold. 
 
1.3 Aim of this Study 
The objective of this study was to improve synthetic graft properties by integrating topographical 
properties and biochemical cues in the grafts. Two types of scaffolds already under investigation 
as potential graft materials were investigated in this study; poly-(vinyl alcohol) (PVA), a synthetic 
polymer, and a polysaccharide-based scaffold composed of the polysaccharides pullulan and 
dextran. To achieve this goal, the following individual strategies were applied to each of the two 
types of materials: 
1. Integration of polyelectrolyte-complexation (PEC) fibers with the polysaccharide and PVA 
scaffolds was done. As PEC fibers have been shown to perform the controlled release of 
various biologics encapsulated in the fibers, incorporation of fibers into the scaffold would 
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improve the ability of the resultant composite scaffold to perform the sustained release of 
biologics. 
2. The development of a novel method for patterning the surface of a cross-linked PVA film, to 
introduce surface topographical cues for endothelial cell attachment. Gratings of different 
dimensions were used to further determine if variations in surface topography would affect 
cell adhesion to the PVA film. 







































STMP-crosslinked hydrogels based on polyvinyl alcohol and pullulan-dextran for use as vascular grafts 
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Background - Treatment of Peripheral Artery Disease 
2.1 Current treatment methods 
Treatments for PAD can be divided into two categories, non-surgical and surgical. Non-surgical 
procedures are preferred as a fair portion of PAD patients are considered high-risk candidates for 
surgery. One option is a pharmaceutical approach, where patients are subjected to intravenous 
infusion of agents, such as anti-platelet, anti-coagulant, thrombolytic and vasoactive agents, to 
prevent and reduce further blockage and relieve pain [5]. Physiologically, in patients with lower 
limb peripheral artery disease (LLPAD), obstruction generally occurs via activation of the 
coagulation cascade and platelets, and they express elevated levels of fibrinogen and increased by-
products of platelet degranulation. Hence, anti-coagulant and anti-platelet drugs work to augment 
the coagulation pathway and slow disease progression. Vasoactive agents influence the vasomotor 
tone of vessels. Vasodilators are thus applied in arterial disease for widening vessel diameter, 
improving blood flow through the affected vessel as well as reducing blood pressure. 
 
2.2 Non-surgical approach 
Of the non-pharmalogical and non-surgical approaches, physical exercise has been shown to 
alleviate claudication symptoms, possibly by favourably affecting the intermediary metabolism of 
skeletal muscle and improving oxygen extraction in the legs [6,7]. Overall, such approaches are 
considered conservative treatments, used to improve local blood circulation to render the limb 
tissue viable until natural physiological processes kick in, ideally development of collateral 
circulation  bypassing the site of blockage. However, non-surgical treatments are ultimately done 
to delay surgical intervention to the limb or to supplement as post-surgical treatments, and are 




2.3 Surgical approach 
2.3.1 Amputations 
In the case of surgical techniques, amputations are typically a last resort for preserving the health 
of a patient with critical limb ischemia, and are and are performed in the case of severe  arterial 
disease. However, the procedure is associated with high patient morbidity, mortality and cost, and 
burdens the patient with a mutilative disability.  
 
2.3.2 Endovascular surgery 
As most patients are often elderly and frail with multiple coexisting health issues, minimally 
invasive procedures such as angioplasty and atherectomy are a preferred treatment option as 
opposed to undergoing open surgical revascularization, where health risks are high and recovery 
durations are long [11]. 
 
Balloon angioplasty and stenting are typically performed in tandem.  During dilation, the 
surrounding plaque is fractured and the tissue media stretched with the effect of re-opening the 
vessel. However, the process has undesirable accompanying effects such as damage to the media, 
desquamation of the endothelium from stretching, as well as neointimal formation due to over-
proliferation of smooth muscle cells and potential embolization [12]. In addition, plaque fractures 
may extend beyond the site of angioplasty treatment. All these tend to increase the risk of the 
entire vessel segment to restenosis or occlusion, thereby replacing one vascular problem with 
another. 
 
With recent advances to improve on the long-term patency of angioplasty and stenting, drug-
coated stents were introduced targeting the inhibition of neointimal formation and inflammation 
[13]. Two such drugs used are sirolimus and paclitaxel [14]. While both drugs have been shown to 
inhibit smooth muscle cell proliferation, endothelial cell proliferation is invariably inhibited as 
6 
 
well, leaving the stent surface exposed for thrombosis formation. In addition, metal as a stent 
material remains subject to inflammation and thrombosis, prompting research into biocompatible 
and biodegradable polymers as stent material candidates [13]. Ultimately, the goal of inhibiting 
neointimal hyperplasia has been acknowledged as a superficial solution to the deeper issue of 
encouraging positive vessel healing mechanisms.  
 
Atherectomy involves the selective removal of atheromatous  materials by cutting, pulverizing or 
shaving via a mechanical catheter-deliverable endarterectomy device [15], and is used for PAD 
patients suffering from heavily-calcified or intimal hyperplastic lesions and eccentric stenosis. 
However, atherectomy demonstrates no overall improvement on restenosis rates over angioplasty. 
The unavoidable vessel wall trauma induced from the procedure invariably leads to intimal 
hyperplasia, yielding poor intermediate and long-term patency rates. 
 
As such, although endovascular surgeries have become favoured over open surgery bypasses in 
recent times, the frequency of surgical revascularization procedures needing secondary 
intervention has also increased. A population-based study in South Carolina on the impact of 
endovascular techniques in the recent decade has shown that, although a pronounced shift in 
favour of endovascular procedures over bypass surgeries, the number of secondary procedures has 
increased to maintain the same limb-salvage efficacies as that of the pre-endovascular era. 
Moreover, the number of amputations performed has not significantly changed [11]. These are 
indications that, although endovascular surgeries are quick, less invasive and convenient, they are 







2.3.3 Vascular grafts 
Surgical bypass of occluded arterial segments had been the mainstream choice of surgical 
treatment in the previous decade [16]. An open-surgery procedure, it involves the creation of a 
separate conduit around the blocked vessel for blood flow using a graft. Ideally, autologous vessel 
grafts should be used to prevent biocompatibility problems and achieve high graft patency rates 
[17], thus the autologous saphenous vein and mammary artery remain the gold standard for use as 
vascular grafts in bypass surgery [18,19]. Unfortunately, such graft sources are scarce as 
autologous veins are not available or inadequate in up to 40% of PAD patients, due to the typical 
presence of coexisting diseases such as venous thrombosis or varicose veins [17]. Other problems 
such as incompatible calibre and previous use [20] also limit the utilization of autologous vessels. 
In addition, the procedure involves an extra step of harvesting healthy vessel, thus subjecting the 
patient to multiple surgical procedures and making the operation more demanding and time-
consuming. Relatively frail patients might not withstand the longer anaesthetic or the longer 
recovery time [21]. 
 
Tissue-engineered grafts were thus proposed to counter the abovementioned problems and yet 
maintain the biocompatibility and patency standards of the autologous vessel. Synthetic materials 
still posed problems of having inherent thrombogenic properties. Hence, various research groups 
had initially approached the problem from a wholly biocompatibility perspective, which intuitively 
utilized collagen or fibrin-based scaffolds seeded with native cells to mimic native vessel 
constituents. However it became clear that, regardless the configuration employed, the scaffolds 
were mechanically inferior to native arterial tissue, being unable to achieve good tensile strengths 
and clinically useful burst pressures [22-24]. Moreover, the tunica media of native vessels 
comprises an abundant amount of elastin fibers, which help prevent dynamic tissue creep and 
convey elastic recoil against pulsatile blood flow. Elastogenesis, or the secretion of elastin by 
smooth muscle cells, was generally absent in static in-vitro culture of collagen-based vessels. 
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Although it was later shown that mechanical stimulus, scaffold material and growth factors 
promoted elastin deposition to a limited extent, the mechanisms for elastin biosynthesis remain 
largely unknown [25]. 
 
In addition, protein-based scaffolds are susceptible to rapid degradation by the immune system 
[26]. As such, stronger, degradable synthetic materials such as poly(l-lactic) acid or poly(lactic-co-
glycolic acid) have been brought into consideration as scaffold materials, to be eventually 
degraded after vessel repair and graft integration completes. Tissue-engineered grafts grown in-
vitro are also subject to problems of patient cell availability, on top of requirements for logistics, 
time and “in house” specialist cell-culturing facilities [17]. One such method was developed by 
L’Heureux et al., which involved rolling cultured cells sheets together and culturing the tubular 
construct to recreate the three vessel layers – tunica adventitia, media and intima – in the tissue-
engineered graft. Although having excellent burst pressure, the procedure required 3 months of 
culturing and maturation. Moreover, lack of elastin content in the matured graft led to compliance 
mismatch and subsequent occlusion within 7 days after implantation into dog femoral arteries [27]. 
 
With improvements to be made in the various techniques of treating PAD, synthetic grafts still 
occupy a substantial treatment niche; they are readily available, easily manufactured with the 
desired properties and relatively cheap. Since the introduction of synthetic materials for vascular 
grafts in the 1950s, a variety of materials have been applied and compared as vascular graft 
candidates, with polytetrafluoroethylene (PTFE) and Dacron emerging the most widely-used 
materials today. PTFE is a relatively stiff and inert fluorocarbon polymer, prepared and used as 
expanded PTFE by extrusion and sintering, while Dacron is a fibrous polyester that can be woven 
or knitted into grafts. Both materials are bioinert and do not interact with tissue, thus are used with 
excellent results in lower limb bypass grafts (7-9 mm). However, PTFE and Dacron grafts have 
poor patency and rapidly occlude when used in small-diameter arteries (<6 mm) (37). 
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Unfortunately, a significant number of peripheral vascular repairs below the knee involve arteries 
of less than 6 mm in diameter [28], greatly limiting their use in PAD treatment.  
 
2.4 Properties influencing synthetic vascular graft patency 
Surface chemistry of the graft, especially on the blood-contacting lumen surface, is crucial in graft 
patency. Synthetic materials have been shown to be inherently thrombogenic. This is especially so 
in smaller arteries where blood flow is relatively slow; plasma proteins are able to adsorb and 
accumulate on the graft lumen wall without being swept away by high wall shear stress, which 
leads to platelet adhesion to the adsorbed proteins and subsequent activation [29]. This acute 
response of thrombosis is followed eventually by anastomotic hyperplasia and ultimately, graft 
failure [30].  
 
Two basic surface chemistry properties – electrostatic charge and surface wettability - have been 
shown to influence material thromboresistance.  Materials such as heparin have anti-thrombogenic 
properties due to their hydrophilicity and net negative charge. PTFE and collagen also possess a 
net negative charge. However, these materials still cause platelet activation and subsequent 
thrombosis. Platelet activation on PTFE surfaces occur via contact activation of the coagulation 
cascade, starting with the adherence and autoactivation of Factor XII to the PTFE surface [8]. 
Collagen interacts directly with platelet receptors, or indirectly via plasma von Williebrand factor, 
which initiates thrombosis [10]. As such, charge is not an encompassing factor in determining 
thromboresistance. 
 
As native arteries are constantly subjected to pulsatile flow forces, the criteria for graft mechanical 
properties are fairly stringent. Mechanical characteristics of grafts such as compliance, Young’s 
modulus and size have considerable potential in determining graft patency [17]. Graft compliance 
is a widely-acknowledged benchmark for graft patency, as compliance mismatch between the graft 
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and vessel wall may contribute to intimal hypertrophy, turbulent blood flow and impedance 
mismatch or disrupted wall shear stress [32]. 
 
While compliance is a rough, endpoint measurement on a graft combining both composition and 
dimension, the Young’s modulus gives information on only material stiffness, from which 
dimensions may be calculated for designing a graft with optimal mechanical properties. In this 
respect, materials such as Dacron and PTFE, with Young’s modulus of 14 GPa [44] and 0.5 GPa 
[17] respectively, face graft patency problems as they are stiffer than native arteries, which are 
estimated to be around 0.4 MPa [33,34]. 
 
A significant difference in graft-to-host artery diameters would lead to undesirably high shear 
stresses, which could lead to anastomotic suture line disruption and anastomotic aneurysm 
formation [35]. In-vitro and in-vivo studies by Panasche et al. with prosthetic Dacron grafts 
showed the graft-to-host diameter ratio had to fall within the range of 1.0 to 1.4 for Dacron, while 
going beyond resulted in sharp increases in shear stress values [36]. Although the range varies 
slightly for different materials or autologous grafts, graft patency is still optimal when the 






















3.1 Materials for vascular grafts 
As mentioned previously, PTFE and Dacron have long been the choice materials for current 
prosthetic graft implants. Expanded PTFE was first used by Matsumoto in 1973 for arterial bypass, 
and to date remains unrivalled in its success rate [37], although clinical long-term patency rates 
have remained poor for small diameter grafts [20]. Dacron grafts similarly exhibit poor 
performance in small-diameter vascular grafts, due to blood and vascular tissue reactivity to the 
material, resulting in inflammation, neointimal proliferation and inhibition of cellular regeneration 
[17]. Both materials have low compliance, further diminishing their potential for vascular implants 
[38]. 
Another synthetic material that has shown promise is polypropylene, which has high tensile 
strength (400 MPa) that can be moduluated for desired graft mechanical and biological properties 
by varying the fiber diameter and weaving conditions, offering an advantage over ePTFE and 
Dacron for small diameter vascular grafts [17].  Grafts constructed of polypropylene, which 
possesses greater biocompatibility and relatively low inflammatory rate, were shown to have 
higher patency one year after implantation compared to grafts of ePTFE or Dacron. A confluent 
endothelialized luminal surface was observed for the polypropylene grafts by one month [39]. The 
findings with polypropylene thus show the importance of the nature of the blood-contacting 
surface and biomechanical properties of the graft in determining patency. 
 
Poly-(vinyl alcohol) (PVA), being biocompatible and non-thrombogenic due to its hydrophilic 
nature, has been a popular synthetic material candidate for biological applications ranging from 
contact lenses to coatings for sutures and catheters. In the field of vascular tissue engineering, 
various methods of crosslinking PVA have been explored in graft fabrication. One of the earliest 
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methods adopted was the repeated freeze-thawing of a PVA solution to physically crosslink the 
PVA chains and create an insoluble gel [40]. While the process is simple and straightforward, gels 
produced via this method tend to possess low thermal and long-term stability [41,42]. PVA 
chemically cross-linked with glutaraldehyde exhibits better stability than freeze-thawed PVA, 
however problems arise due to the residual toxicity from glutaraldehyde and subsequent leaching 
of cytotoxic monomers following implantation [43]. Irradiation of PVA has the advantage of 
sterilization and cross-linking in one step, although mechanical properties of the scaffolds yielded 
are relatively poor [41].  
 
Chaouat et al. used sodium trimetaphosphate (STMP), a non-toxic compound commonly used in 
the food industry, to crosslink PVA in aqueous solution [44]. The resultant vascular graft exhibited 
excellent suture retention strength and compliance better approximating to native arterial tissue 
compared to PTFE and Dacron. Grafts implanted into rat aortas showed patency rates of 83% at 1 
week post-implantation, with no detectable aneurysm formation. As the cross-linking process does 
not involve toxic components and organic solvents, the problem of residual toxicity is nullified 
and potential possibilities such as the incorporation of biological compounds for controlled release 
in the graft are open for consideration. However, the inherent hydrophilic nature of PVA does not 
encourage cell attachment, hence the material makes for a poor support frame for cell growth and 
tissue regeneration. 
 
Natural materials, most prominently collagen, have also been considered as graft material. 
Although collagen is advantageous in promoting cell attachment and recellularization, it is 
inherently thrombogenic [45] and, with the absence of a basement membrane typically present in 
native arteries, would still be subject to thrombus formation. In addition, the mechanical strength 
of pure collagen is insufficient to satisfy graft implant criteria. A study by Berglund demonstrated 
that addition of elastin to collagen tubes successfully improved graft mechanical strength and 
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viscoelasticity [46], the latter being a long-standing problem with implanted arterial grafts. 
Preliminary studies have also suggested that elastin exhibits less platelet adhesion compared to 
collagen [47]. However, incorporating elastin with collagen in the graft fabrication process has 
been difficult due to the low solubility of elastin [20]. Alternatively, elastin has been successfully 
electrospun, using organic solvent, with polydioxane to yield grafts with good mechanical 
compliance and cell attachment properties [48]. 
 
Pullulan is a hydrophilic, naturally-derived polysaccharide produced from starch fermentation by 
the fungus A. pullulans [49]. Pullulan displays biochemical similarities to the extracellular matrix 
(ECM), thus making it non-antigenic and non-immunogenic, and hence a promising candidate for 
vascular grafts. Dextran, another biocompatible polysaccharide, is synthesized from sucrose by 
bacteria and consists of glucose units joined mostly by α1,6-glycosidic linkages, with side chains 
α1,2-, α1,3- or α1,4-linked to the backbone. Recently, Chaouat et al. investigated the use of a 
combination of pullulan and dextran polysaccharides to fabricate small diameter vascular grafts 
and subsequently implanted the constructs into rat aortas [50]. The growth of a pseudo-intima on 
the graft lumen-blood interface was observed, indicating potential in the use of the polysaccharide 
graft as a scaffold for vascular tissue regeneration. 80% of the implanted grafts remained patent 
and dimensionally stable over 8 weeks of implantation, a lower patency rate than conventional 
grafts. Blood clots were evidenced on the occluded grafts, indicating the limited anti-
thrombogenicity of the graft. In addition, the grafts were not mechanically strong enough to 
withstand aortic pressures in-vivo, and had to be reinforced with a nylon mesh prior to 
implantation. 
 
Another study was conducted by the same group on utilizing pullulan scaffolds for smooth muscle 
cell culture [49]. Cells were observed to express good adherence, attachment and proliferation to 
14 
 
the gel surface, suggesting that the scaffold could be used to regenerate the tunica media of the 
artery, which would greatly contribute to improving the mechanical properties of the graft. Yet 
another study demonstrated that the pullulan scaffolds were also conducive for endothelial 
progenitor cell attachment [51]. Both studies point to the potential use of pullulan grafts to 
regenerate both the smooth muscle and endothelial layers, which would in turn improve the 
thromboresistance and mechanical properties of the pullulan graft.  
 
3.2 Endothelialization of synthetic vascular grafts 
As the small diameter synthetic graft is prone to thrombosis and foreign material inflammatory 
response, it was proposed that a confluent layer of endothelial cells in the lumen of the graft would 
improve synthetic graft patency. Endothelial cells form a monolayer connected by tight junctions, 
and serve to prevent platelet deposition and inhibit smooth muscle cell migration to the subintimal 
space [28]. Moreover, the vascular endothelium also regulates physiological processes such as 
shear stress mechanotransduction, oxygen diffusion, macro-molecular permeability, coagulation 
and interaction with immune cells [52]. The vascular endothelium is essential for compensating 
the viscoelastic losses of the vessel wall [53]. Thus, rather than mimicking the native vessel lumen 
surface, introducing a confluent endothelial lining to the graft would provide thromboresistance 
and physiological responsiveness to the prevailing haemodynamic conditions. 
 
In 1978, Herring et al. first reported endothelial cell seeding in grafts subsequently implanted in 
canine infrarenal aortas. A significantly higher rate of patency was observed, with 76% of the 
endothelial cell-seeded grafts remaining clot-free, compared to 22% of non-seeded ones [54]. To 
date, a number of methods have been devised for improving seeding endothelial cells to grafts. 
Such seeding methods employed include magnetic, electrostatic, vacuum and rotational cell 
seeding, as well as coating biological “glues” such as fibronectin on the graft lumen surface to 
improve cell adhesion [55,56]. However, mechanical methods of cell seeding compromise the 
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morphology and viability of the cells, and their requirements for long cell seeding durations pose 
practical limits on performing cell-harvesting and implantation on the same day, as well as prompt 
surgical treatment. 
 
Another approach is to promote endothelialisation of the graft lumen after implantation. 
Spontaneous endothelialisation  occurs by direct migration of endothelial cells from the 
anastomotic edge into the graft, transmural migration of endothelial cells and cell transformation 
from endothelial progenitor cells. Surface modification of the synthetic graft lumen with additives 
such as anti-CD34 antibodies and vascular endothelial growth factors has demonstrated increased 
endothelialisation in-vivo [29]. However, spontaneous endothelialisation is still a slow and limited 
process. 
 
A fairly recent field of research explores how surface topography affects cell behaviour. It is 
generally acknowledged that cells are able to sense the stiffness and contours of its underlying 
surface, and by mechanotransduction, the mechanical stimulus is converted into internal chemical 
signalling pathways, which in turn affects cell behavioural patterns such as attachment, 
morphology, migration and proliferation. In endothelial cells, it was observed that surface porosity 
enhances endothelialisation [29], a preliminary indicator of the influence of surface roughness on 
endothelial cell behaviour. Another study by Zorlutuna et al. showed that nano-grating patterns 
improved cell retention under shear stress [57], a promising prospect in maintaining a confluent 
endothelium under flow conditions in-vivo.  
 
In terms of cell morphology, the observed alignment of endothelial cells to linear patterns, both on 
the micro- and nano-scale, has been well-characterized [58-62]. The implications of this 
observation are not immediate, as endothelial cells typically assume a cobblestone morphology 
rather than an elongated one in static conditions. Cell-cell contact has also been seen to override 
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the influence of the underlying topography, as cells revert to the cobblestone morphology upon 
becoming confluent. However, probing further on the influence of topography on endothelial cell 
migration, the reason for cells to assume an elongated morphology becomes more apparent. Using 
grating patterns of 200nm depth and 2 µm groove width, Biela et al. demonstrated that human 
coronary artery endothelial cells not only displayed an elongated morphology along the 
longitudinal grating axis, but also had a tendency to migrate in the axis direction as well [58]. 
Similarly, Uttayarat et al. also showed that cells migrated overwhelmingly in the direction parallel 
to the longitudinal axis, maintaining a steady migration speed over the 4-hour course of 
observation. This phenomenon was enhanced in the presence of moderate to high flow [62], which 
implied that topography might enhance cell migration under shear force in native physiological 
conditions. 
 
Although the exact cellular pathways that link cell sensing of the underlying topography to cell 
migration are still unknown, the mechanotactic process of endothelial cell migration in response to 
fluid shear stress has been better established and characterized. Embedded glycoproteins on the 
apical side of the cell membrane transmit the external shear stress force to align the cell’s 
cytoskeleton [63], causing the cell cytoskeleton to elongate in the direction of the shear stresses. 
This in turn activates the motogenic signalling pathways in the cell, namely the Rho GTPases [64]. 
Cell migration thus happens when Rac, part of the Pho GTPase family, is activated and promotes 
actin polymerisation and hence lamellipodia protrusion in the flow direction. Rac also inhibits 
RhoA activity on the lagging end of the cell, inducing contraction and thus rear detachment and 
migration [65]. Topography thus seems to extend from the mechanotactic process of cell migration, 
a natural migration mechanism that occurs alongside chemotactic and haptotactic processes [64].  
Along with the abovementioned effect of topography on endothelial cell behaviour, this would 
thus be an indication for the potential use of linear-patterned graft lumens to provide contact 
guidance cues for spontaneous endothelial cell migration. 
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3.3 Controlled release of growth factor in synthetic vascular grafts 
The vascular endothelial growth factor (VEGF) family play key roles in growth and differentiation 
of the vasculature. The family comprises six secreted glycoproteins; VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and placenta growth factor, of which VEGF-A plays a key functional role in 
angiogenesis which other VEGF family members cannot compensate for in its absence [66]. 
Homozygous or heterozygous deletion of the encoding gene in mice has proven embryonically 
lethal, resulting in vasculogenesis and cardiovascular defects [67,68], while pathological 
conditions involving increased angiogenesis such as psoriasis, arthritis, macular degeneration and 
retinopathy have been linked to VEGF-A  [69]. 
 
VEGF-A is a homodimeric glycoprotein that exhibits binding affinity to both VEGFR-1 and 
VEGFR-2 tyrosine kinase receptors found on endothelial cells [70]. Human VEGF-A exists in six 
main isoforms, generated by the alternative exon-splicing of the VEGF mRNA. An important 
difference between each isoform is their isoelectric point and their binding affinity to heparin [71]. 
Of these, VEGF165, an isoform consisting of 165 amino acids that exhibits relatively moderate 
affinity to heparin, has reportedly the highest biological potency amongst other variants [72,73]. 
Compared to VEGF121, which has no affinity for heparin, VEGF165 is able to bind to neuropilin-1 
via its heparin-binding domain, which presents VEGF to VEGFR-1 or VEGFR-2 in a way that 
enhances the signal transduction cascade [70]. In contrast, VEGF189 and VEGF206 have relatively 
higher binding affinity, and thus are mostly sequestered in the extracellular matrix. Both isoforms 
are only released and become available upon proteolytic cleavage, an action which unfortunately 
simultaneously decreases their biological potency [122]. 
 
Actions of VEGF-A include stimulating microvascular permeability, endothelial cell survival, 
proliferation and migration [76], thus demarcating its pluripotent role in angiogenesis. Dvoark et al. 
proposed that, by rendering the microvasculature permeable to macromolecules, plasma proteins 
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such as fibrinogen and other clotting factors can leak into the extracellular space, creating a pro-
angiogenic environment for endothelial cell migration [123]. Degradation of the basement 
membrane follows, as VEGF induces the production of matrix-degrading metalloproteinases, 
metalloproteinase interstitial collagenase and serine proteases [70]. VEGF-A functions as a 
chemoattractant for endothelial cells, specifically via extracellular gradients of VEGF-A that are 
generated from the secretion of VEGF in the extracellular environment and their subsequent 
diffusion. Such gradients have been found to induce physiological angiogenesis in the early 
postnatal retina [74] as well as in the developing brain and central nervous system [75]. Gerhardt 
et al. showed that endothelial tip cells extend their filopodia in the direction of high VEGF 
concentrations, while endothelial stalk cells were induced to proliferate, resulting in angiogenesis 
in the direction of the VEGF gradient [74]. 
 
Numerous techniques have been used to harness the effect of VEGF in inducing spontaneous re-
endothelialization of synthetic grafts, namely by incorporation of VEGF in or on the surface of the 
graft material [75-77]. In early studies, most grafts were first synthesized before being immersed 
in a solution of growth factor. However, in these cases VEGF there was not much consideration 
for the binding or stabilizing of VEGF to the graft material, and release profiles were characterized 
by high initial burst releases and short release durations. In addition, VEGF is known to possess a 
short half-life of 1 hr in the body, an insufficient time frame for the growth factor to exert any 
therapeutic effect if its release was not well-controlled. The immersion-incorporation of VEGF 
also limited spatial control of VEGF distribution in the graft. Subsequent studies have introduced 
heparin as a scaffold component [78,79], as heparin forms a stable complex with VEGF, thus 
prolonging its half-life in-vivo, as well as regulating its release.  
 
Another method of controlled release involves the encapsulation of biologics during the 
complexation of two polymers. When two oppositely-charged polymer solutions are brought 
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together, a solid fiber may be drawn at the interface of the solutions, a product of the complexation 
between the two polymers. The resultant fiber is known as a polyelectrolyte complexation (PEC) 
fiber. Should a biological compound or drug be mixed into one of the polymer solutions of similar 
charge to itself, the drug or compound can be drawn up during the complexation process and be 
subsequently encapsulated in the resultant fiber formed. This was successfully carried out by Liao 
et al. and Yim et al., where they demonstrated a sustained release profile of growth factors, 
specifically platelet-derived growth factor and transforming growth factor-β3, from a chitosan-
alginate fiber construct [80,81]. Chitosan and alginate each have two ionic groups in their 
repeating units. During the complexation process, the negatively charged carboxylic acid groups of 
manuronic and guluronic acid units in alginate would interact electrostatically with the positively 
charged amino groups of chitosan. The controlled release of growth factor relies on the charge 
interactions between the polyelectrolytes and growth factor. The stability of the polyelectrolyte 
complex formed depends on several factors, such as drawing speed of the PEC fiber at the solution 
interface of the two polymers, charge density and pH. The degree of ionization can be optimized 
by maintaining the pH values of each polymer’s solution at a specific value; chitosan in acidic 
solution and alginate in alkaline solution. Using chitosan with a high degree of deacetylation, and 
hence a high density of positive charge, also allowed for stronger electrostatic interaction.  
 
3.4 Functionalization of PVA and pullulan-dextran vascular grafts 
While PVA and pullulan both possess good biocompatibility properties, patency rates of their 
corresponding vascular grafts still do not satisfy clinical demands, with the abovementioned 
studies highlighting the occurrence of thrombosis and occlusion in implanted grafts. As mentioned 
previously, potential solutions to the problems are to improve cell migration and adhesion in the 
graft, either by introducing biolomolecular cues to the graft, providing a form of contact guidance 
for cell proliferation and tissue regeneration, or integrating a topographical pattern into the lumen 




Although the abovementioned studies have demonstrated that both scaffold types are 
biocompatible and non-thrombogenic to some degree, studies have yet to be done on using both 
scaffolds as vascular graft release reservoirs for growth factors. As the method of cross-linking 
both types of scaffolds does not involve heat or organic solvents, both scaffolds are open to a 
variety of modifications and incorporation of various biologics, without affecting the 
biocompatibility of the scaffold or concern for denaturing or degradation of fragile biological 
molecules. 
 
3.5 Study objectives 
The objective of this study was thus to improve and characterize synthetic graft properties by 
integrating topographical properties and biochemical cues in the grafts. Two types of scaffolds that 
were already under investigation as potential graft materials were used in this study; poly-vinyl 
alcohol, a synthetic polymer, and a polysaccharide-based scaffold composed of the 
polysaccharides pullulan and dextran. Crosslinking of either scaffold could be done using sodium 
trimetaphosphate (STMP), in a process that does not require the use of organic solvents or high 
heat. Thus, it was expected that growth factors encapsulated in scaffolds prepared in such a 
process would better retain their functional integrity and could be used in the grafts as biochemical 
cues for endothelialisation, To achieve this goal, the following individual strategies were applied 
to each of the two types of materials. 
 
Firstly, integration of polyelectrolyte-complexation (PEC) fibers with the polysaccharide and PVA 
scaffolds was done. As PEC fibers have been shown to perform the controlled release of various 
biologics encapsulated in the fibers, incorporation of fibers into the scaffold would improve the 
ability of the resultant composite scaffold to perform the sustained release of biologics. As a 
preliminary investigation of the overall release profile of biologics from the composite scaffolds, 
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BSA and Trypsin were used as model release proteins. Subsequently, the release of vascular 
endothelial growth factor (VEGF), a signal peptide shown to promote endothelialisation, was also 
investigated in polysaccharide scaffolds. 
 
The relatively long crosslinking duration of PVA allowed the development of a solvent-casting 
method for patterning the surface of PVA film, to introduce surface topographical cues for 
endothelial cell attachment,. Gratings patterns were chosen as gratings have been shown to 
facilitate endothelial cell migration. To further determine if variations in surface topography would 
affect cell adhesion to the PVA film, cells were seeded on a range of grating dimensions. This also 
served as a preliminary observation to the dimension of grating that may be optimal to the process 








4.1 Polyelectrolyte complexation  fiber fabrication 
To functionalize the scaffolds for controlled release of biologics, polyelectrolyte complexation 
(PEC) fibers were incorporated into the polysaccharide and PVA scaffolds to form their respective 
composites. In this study, chitosan and alginate were the choice polymers for PEC fiber fabrication. 
 
Chitosan was purified, following Liao et al.’s procedure [80]. Chitosan (1% w/v in 2% v/v acetic 
acid) was dissolved, filtered and adjusted to neutral pH with 0.5 M NaOH. The precipitated 
chitosan was repeatedly centrifuged at 3500 rpm for 5 min and re-suspended in DI water three 
times, and thereafter lyophilized for storage. The purified chitosan was then dissolved in 0.15 M 
acetic acid solution at 1% w/v and subsequently adjusted to pH 6 with 0.5 M NaOH. alginic 
powder (Sigma Aldrich) and heparin (Sigma Aldrich) were both prepared by dissolving in DI 
water at 1% w/v respectively.  
 
To prepare for fiber formation, purified chitosan was dissolved in 0.15 M acetic acid solution (1% 
w/v) and adjusted to pH 6, while the alginic acid powder was dissolved in DI water at 1% w/v. To 
produce the chitosan–alginate fiber, 20 µl of chitosan solution was first brought in contact with 20 
µl of alginate solution on a polystyrene dish surface. A continuous strand of fiber was drawn 
vertically from the solution interface by a speed-controlled motor onto either a pair of collecting 
needles or the PVA graft, at an approximate speed of 1 mm/s. With respect to PEC fiber 
incorporation into PVA grafts, heparin was additionally used in fiber formation, and alginate and 
heparin solution ratios were varied to a final total concentration of 1% w/v, to assess the optimum 
controlled release profile of growth factor from the composite construct. 
Figure 1: Set up for polyelectroly
For encapsulation of biologics,
Shenyang, China) or VEGF
either the chitosan or alginate solution prior to the fiber drawing. 
was added to alginate solution at a concentration of 2.5 mg/ml, while the positively charged VEGF 
was added to the chitosan solution
binding to VEGF receptors on endothelial cells in the pH range of 7.0 to 5.5 [125], the bioactivity 
of VEGF could be inferred to be retained in the chitosan solution of pH 6. 
this manner to prevent premature protein
completion of fiber drawing, 500 µl of phosphate buffered saline (PBS) was used to collect the 
remaining pool of chitosan-alginate solution, from which the concentration of rem
was determined to assess encapsulation efficiency.
 
4.2 Polysaccharide scaffold
4.2.1 Fabrication of polysaccharide
A pre-gel mixture of pullulan/dextran 75:25 was prepared with a total concentration of 
in deionized (DI) water (pullulan,
500,000, Sigma Aldrich). The
that found the ratio to be optimal to obtain mechanically
[50]. For porous polysaccharide scaffolds, sodium bicarbonate 
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 MW 200,000, Hayashibara Inc., Okayama, Japan; dextran MW 
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incorporated at a concentration of 20% w/v. The mixtures were either used immediately after 
preparation or stored in sealed containers at 4oC for later use. 
 
One gram of the pre-gel mixture was mixed with 100 µl of 10 M sodium hydroxide (NaOH) 
(Sigma Aldrich) to activate the polysaccharide hydroxyl side groups for cross-linking. Chemical 
cross-linking of polysaccharides was carried out using sodium trimetaphosphate (STMP) (Sigma 
Aldrich), which was prepared in DI water at 11% w/v. Crosslinking occurs with STMP 
functioning as a bi-functional crosslinker between activated hydroxyl side groups of the 
polysaccharides. Polysaccharides mixed with STMP were then poured into a cylindrical mould of 
10 mm diameter, and composite scaffolds were prepared by immersing the dried PEC fibers into 
the mould along with the pre-gel mix. The scaffolds were thereafter incubated at 37oC for 30 
minutes. Scaffolds containing sodium bicarbonate were then immersed in a 20% acetic acid 
solution (J.T. Baker) for 15 minutes to induce porosity. Scaffolds were thereafter washed four 
times with PBS to neutralize the remaining acid and remove excess reactants. 
 
4.2.2 Controlled release studies 
Controlled release studies were first performed using BSA as a model molecule, to determine 
whether a sustained release of biologics could be obtained from the composite scaffold of 
polysaccharide and PEC fibers. Once the method for encapsulation was established and optimised, 
VEGF was then used as the encapsulated biologic for the controlled release study. For controlled 
release studies using BSA, both porous and non-porous scaffolds were used in the experiment to 
determine any differences in release profiles between both types of scaffolds, as well as whether 
the extra step of inducing porosity by immersing scaffolds in acetic acid solution would affect the 
overall percentage encapsulation of the biologic in the scaffold. 
Controlled release assessment was performed by immersing scaffolds in 1 ml of sterile PBS in a 
24-well plate at 37oC. A total of 250 µg of BSA was encapsulated in 100 mg of PEC fibers, while 
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100 ng of VEGF was encapsulated in about 40 mg of PEC fibers. In the case of VEGF controlled 
release studies, the release solution was prepared by dissolving 1% w/v BSA in PBS. This was 
done to prevent losing significant amounts of VEGF by adsorption to well surfaces and peptide 
degradation. At each designated assay time point, the release solution was completely drawn out 
and replaced with 1 ml of fresh release solution. Release solutions were stored in -80oC for 
subsequent testing. BSA concentrations were quantified using the BCA assay kit (Pierce), and 
VEGF concentrations were assessed with the Duo-Set ELISA kit (R&D Systems). A total of 3 
samples per scaffold type were used in the experiments. 
 
4.2.3 Cell culture studies on polysaccharide scaffolds 
Fibroblast adhesion was assessed on the polysaccharide and polysaccharide-fiber composite 
scaffolds, to determine if the scaffolds would be susceptible to stenosis. L929 mouse fibroblasts 
(ATCC, passage 20-23) were cultured with Dulbecco's modified Eagle's medium (NUMI, 
Singapore) supplemented with 10% fetal bovine serum (NUMI, Singapore) and 1% penicillin/ 
streptomycin (Sigma Aldrich). Cell cultures were washed with sterile PBS and harvested using 
trypsin (Gibco) from the culture flask and assessment was made of their density via 
haemocytometer and viability by trypan blue before cell seeding. Three different types of scaffolds; 
polysaccharide scaffold without fibers, scaffolds with bare fibers and scaffolds with fibronectin-
incorporated fibers, were used in this study. Prior to cell seeding, scaffolds were sterilized by UV-
irradiation for 1 hour. The experiment was performed in triplicates in 24-well plates. 200µl of cell 
suspension containing 2 x105 cells was added gradually to the scaffolds and cells were allowed to 
adhere for 1 hour, after which each scaffold-containing well was topped up with 1 ml of fresh 
culture medium. The cultures were incubated at 37oC with 5% CO2 and maintained in culture for 




4.2.4 Scanning electron microscopy (SEM) study of scaffolds 
SEM studies were carried out to assess the structure of the polysaccharide scaffolds and the 
morphology of the L929 cells in the scaffolds. Cacodylate buffer was prepared beforehand by 
preparing 0.1 M sodium cacodylate (Sigma Aldrich) and 3 mM CaCl2 (Sigma Aldrich) in DI water 
and adjusting the solution to pH 7.  After 7 days of culture, cells and scaffolds were fixed using a 2% 
v/v glutaraldehyde (Sigma Aldrich) solution in cacodylate buffer. Scaffolds were then washed 
thoroughly in cacodylate buffer solution. Ethanol dehydration was carried out by immersing 
scaffolds in ethanol-buffer solutions of increasing ethanol concentrations (25%, 50%, 75%, 90%, 
100%). Scaffolds were then subjected to dry with hexamethyldisilazane (Sigma Aldrich), followed 
by sputter-coating with gold (JEOL JFC 1600 Fine Gold Coater, 10 mA, 90 secs). The surface 
structure and morphology of the scaffolds and cells respectively were then observed with a FEI 
Quanta 200F SEM. 
 
4.3 PVA tube and film fabrication and study 
4.3.1 Preparation of patterned moulds 
Patterned polystyrene (PS) moulds were prepared from polydimethylsiloxane (PDMS) (Dow 
Corning) master templates by heat embossing. The templates prepared had patterns of parallel 
channels with groove and ridge widths of 10 µm and 250 nm depth, 2 µm and 2 µm depth and 250 
nm with 250 nm depth. A square of PS (Corning Incorporated, Corning, NY) was heated on a 
hotplate to 125 oC, above the polymer’s glass transition temperature. Thereafter, the PDMS master 
was placed pattern side facing down on the PS piece, and a constant pressure was applied for 2 
minutes. The PS piece was cooled to room temperature, while maintaining the same pressure on 
the construct for an additional 1 minute. The patterned PS pieces were then glued with a silicone 
adhesive to the bottom of petri dishes (diameter 35 mm) and left to dry for 2 days before use. As a 




4.3.2 Preparation of pre-cross-linked PVA mixture 
PVA solution of 10% w/v was first prepared by dissolving 10g of PVA (Sigma-Aldrich Inc., Saint 
Louis, USA, 85-124 kDa; 87-89% hydrolyzed) in 100ml of distilled water and stirring at 90oC 
until the PVA had dissolved. Temperature and stirring conditions were maintained for an 
additional 4 h to ensure dissolution of all aggregates and the obtained solution was then cooled to 
room temperature. The solution was stored at 4oC until further use. STMP was dissolved in 750 µl 
of DI water at a concentration of 15% w/v and added to 10 ml of PVA solution, which was stirred 
to ensure homogeneity. 300 µl of NaOH solution at 30% w/v was then added drop-wise while 
stirring, and thereafter the entire solution was kept stirring constantly for 10 minutes. The pre-
cross-linked mixture was used immediately after mixing. 
 
4.3.3 Fabrication of patterned PVA films 
From the pre-cross-linked mixture, 1 ml of the resultant mixture was poured into each patterned 
mould and centrifuged at 4000 rpm for 15 minutes to rid of bubbles in the bulk solution. The 
solution was thereafter degassed in a desiccator for 15 minutes, followed by another centrifugation 
at 4000 rpm for 1 hr to eliminate the remaining bubbles. The moulds were left at room temperature 
until the water was completely evaporated and a constant weight was obtained.  
 
4.3.4 Fabrication of PVA tube scaffolds 
Patterned PVA films were wet slightly with DI water and wrapped two times around a 1.7 mm 
diameter glass rod, patterned side facing the rod lumen. Pre-cross-linked mixture was prepared as 
given above, but left to stand for 2 hours until the pH fell to 8.2 prior to use. Glass rods bearing the 
tubes were then repeatedly dipped six times, at 10 minute intervals of drying time per dipping to 
allow for cross-linking, into the pre-cross-linked mixture to coat the films and form PVA tubes. 
For PVA tubes that were to have PEC fibers incorporated, only four dippings into the pre-cross-
linked mixture were done. The newly-fabricated tubes were thereafter left on the glass rods to 
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cross-link overnight. Fully cross-linked tubes were washed four times in PBS at 15 minute 
intervals each, and the finished constructs were removed from the supporting glass rod. 
 
4.3.5 SEM study of PVA film surface and tube lumen topography 
PVA films were washed four times in PBS at 15 minutes intervals before being left to dry 
overnight in a fume hood. Dried films were gold sputter coated (10 mA, 90 secs) mounted, 
patterned side facing up, on aluminium stands for visualization by SEM. PVA tubes were also 
dried in a similar fashion. Prior to gold sputter coating and SEM imaging, PVA tubes were 
additionally freeze-fractured along their cross section at a slant angle to expose the tube lumen. 
 
4.3.6 Permeability assessment of PVA films 
As the PVA tubes were fabricated by a process that involved simultaneous evaporation and cross-
linking, PVA chains within the tube scaffold would have been more densely packed compared to 
the polysaccharide scaffold, which undergoes a cross-linking process without evaporation. As such, 
it was necessary to investigate the permeability of the cross-linked PVA to macromolecules before 
determining the scaffold’s controlled release properties. Trypsin and BSA were chosen as model 
molecules for this experiment as their molecular weights were of similar order of magnitude to 
that of VEGF (Table 1). Trypsin and BSA were also chosen due to their different charge polarities 
in physiological solution of pH 7.4, in order to determine if permeability of the PVA was 
influenced by charge polarity of the diffusing protein. 
Molecule Molecular weight (kDa) Isoelectric point Charge (pH 7.4) 
Trypsin 23.3 10.1-10.5 
 
Positive 
BSA 66.4 4.7 
 
Negative 
VEGF 45.0 8.55 
 
Positive 
Table 1: Macromolecules of various molecular weights and charges for comparison 
 To assess the permeability of the PVA film to macromolecules, a diffusion chamber was set up as 
shown in figure 1. PVA films of 0.3
polypropylene ring and con
leaving only the cap and locking mechanism.
for injection of solution into the upper chamber. This created
film of about 95 mm2. The setup was assessed for leakage by first sandwiching a piece of non
water permeable polyethylene film in the setup and filling the upper compartment with DI water. 
After 24 hours, the lower compartment was 
system was affirmed to be leak
 
PVA films were then used in the setup for the actual experiment. The upper compartment was 
filled with 300 µl of PBS solution containing
as model proteins for assessing permeability
sodium hydroxide solution. 
The setup was left to incubate at 37
time points over 5 hours. Protein concentrations of the collected solutions were quantified using a 
bicinchoninic acid (BCA) assay kit (Pierce)
Figure 2: Set up of diffusion chamber for protein 
 
 
4.3.7 Controlled release studies for PVA tubes
Before controlled release assessment was performed 
tubes, encapsulation efficiency of the trypsin in PEC fibers was first
 
±0.02 mm thickness were sandwiched 
tainer made from 2 ml Eppendorf tubes with the bottom cut away
 A 6 mm-diameter hole was cut in the cap to allow 
 an available diffusion area 
confirmed to have no leakage of water, thus the 
-proof. 
 1500 ug/ml of protein.  Trypsin and
, and the solutions were adjusted to pH 7.4 using 5 M 
The lower chamber was filled with 500 µl of PBS devoid of protein. 












 BSA were used 
 
-only 
 180 µg of trypsin 
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was encapsulated in PEC fibers by mixing lyophilized trypsin (Invitrogen) in 1% w/v chitosan 
solution and drawing 45 µl of the solution against 45 µl of a 1% w/v solution of 90% alginate and 
10% heparin. Fibers were drawn onto the thoroughly washed PVA tubes that had been subjected 
to only four dippings as described previously. After 2 hours of fiber-drying, PVA-fiber tubes were 
then subjected to an additional two dippings in cross-linked PVA solution and left to dry for 
another 2 hours. 
 
The residue left behind after fiber-drawing was then dissolved and collected in 500 µl of PBS. The 
remaining trypsin in the residue was then quantified with the BCA protein assay kit. After 
encapsulation efficiency was ascertained and the amount of trypsin incorporated into the PVA-
fiber construct was known, the same amount of trypsin was prepared by dissolving in 10 µl of PBS. 
PVA-only tubes that were previously subjected to six dippings were prepared by dehydrating 
thoroughly washed tubes for 2 hours in a desiccator. Thereafter, PVA tubes were each rehydrated 
with 10 µl of the prepared trypsin solution. Both types of scaffolds were then washed briefly with 
PBS for 5 minutes and immediately immersed in a 1 ml release solution of fresh PBS. At each 
designated assay time point, the release solution was completely drawn out and replaced with 1 ml 
of fresh release solution. Release solutions were stored in -80oC for subsequent testing. Trypsin 
concentrations were quantified using the BCA assay kit (Pierce). 
  
4.3.8 Human umbilical vein endothelial cell (HUVEC) culture and PVA film seeding 
HUVEC-Cs (ATCC, 1730-CRL) were grown in EBM-2 MV growth medium (Lonza) in a 
humidified atmosphere at 37oC, 5% CO2, and used between passages 7-9 in experiments. Cells 
were washed with HEPES buffer (Lonza) and trypsinized in 0.05% trypsin (Lonza) to harvest cells. 
Thereafter, cell count and viability quantifications were performed with a haemocytometer and 
trypan blue before seeding on films. Two dimensions of films were used for this study, namely 
those of groove and ridge widths 2 µm and 2 µm depth, and 250 nm with 250 nm depth. 
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Unpatterned PVA films were used as controls in this experiment, and all samples were run in 
triplicate. Films were cut into 1 cm×1 cm squares, and sterilized by UV-irradiation for 20 minutes 
on each side before being transferred to 24-well plates. HUVECs were localized-seeded on films 
at a cell density of 15,000 cells/cm2 and cultures were maintained in a humidified atmosphere at 
37oC, 5% CO2. 
 
4.3.9 Cell morphology studies of HUVECs on PVA films 
PVA is known to resist cell adhesion. As spreading and adhesion is a pre-requisite to cells forming 
a congruent cell layer, this test was carried out to determine if varying the surface topography 
could improve cell adhesion and spread. After 24 hours of culture, cell-seeded films were washed 
with HEPES buffer solution and fixed for 20 minutes using a 4% paraformaldehyde solution. The 
washing step was then repeated and films were treated with a 1:5000 dilution of YOYO-1 
(Invitrogen), a nucleic acid stain, and 10 µg/ml solution of RNAse (Invitrogen) for 2 hours in 37oC. 
Subsequently, samples were washed in PBS and incubated in a 1:200 dilution of a filamentous 
actin indicator, phalloidin-TRITC (Invitrogen) in PBS overnight at 4oC. Films were thereafter 
washed with PBS and affixed to glass coverslips using mounting medium (Fluormount, Sigma 
Aldrich). Stained cells were visualized using a fluorescent microscope (Leica DM IRB, Germany) 
and captured images were subsequently processed with the Java-based image analysis program, 
ImageJ (W. Rasband, http://rsb.info.nih.gov/ij/). 
 
4.3.10 Uniaxial tensile testing 
Uniaxial testing was done to determine the effects of incorporating PEC fibers on the mechanical 
properties of crosslinked PVA. Strips of PVA of 400 g and dimensions of 0.5 mm thickness, 3.5 
mm width and 50 mm length were prepared, with the measurements taken using a pair of vernier 
calipers. 75 mg of PEC fibers were then spun onto each strip, aligned either perpendicular or 
parallel to the long axis of the strips. Thereafter, the constructs were repeatedly dipped in pre-
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cross-linked PVA mixture six times at intervals of 10 minutes and left to dry overnight. The strips 
were then washed four times at 15 minute intervals. The dimensions of the newly-modified strips 
were taken and recorded again prior to testing. Uniaxial tensile testing was done on strips with 
parallel and perpendicular fibers, with an additional control set comprising strips with no fibers. 
Testing was carried out with a tabletop uniaxial testing machine (INSTRON 3345), with the use of 
a 10-N load cell under a cross-head speed of 10 mm/min at ambient conditions. Samples were first 
subjected to a pre-load of 0.1 N before measurements commenced. Four samples were tested for 






Results and Discussion – Fabrication and characterization of polysaccharide scaffolds 
5.1 Polysaccharide scaffolds 
Our focus was oriented towards characterizing the controlled release and cell growth properties of 
the fiber-polysaccharide construct. Polysaccharide tube-shaped scaffolds could not be made 
without the use of a special mould our collaborators had custom-made, which was limited in 
number and expensive to request for. As such, a flat, coin-shaped polysaccharide scaffold was 
used for experiments with the polysaccharide scaffolds. 
 
Cross-linking of the scaffold is carried out in aqueous solution, and the general chemical reaction 
first involves the activation of hydroxyl groups on the polysaccharide chain and ring-opening 
activation of the STMP cross-linker by sodium hydroxide. Thereafter, two activated hydroxyl 
groups on the polysaccharide chains are covalently joined by an activated STMP molecule via two 
nucleophilic substitution reactions, completing the cross-linking reaction. 
 
SEM images of polysaccharide scaffolds showed scaffolds to be highly and uniformly porous. The 
methodology and reagents used in preparing the scaffolds were identical to that of our 
collaborators [49,82,83]. In their study, polysaccharide hydrogels were characterized for scaffold 
porosity as a ratio of the total volume of the pores to that of the whole scaffold. Their group found 
pores of scaffolds prepared with this method to be lamellar and highly interconnected, with pore 
sizes averaging around 500 um and scaffolds overall possessing a porosity of about 50% [83].  
 
From SEM images (Figure 3C), a close-up of the hydrogel also showed the surface to be smooth 
overall, and that the pore interconnectivity within the hydrogel was high. PEC fibers embedded in 
the polysaccharide matrix were still evident as individual strands despite being exposed to the 
harsh alkaline conditions, cross-linking of the surrounding hydrogel and the acidic pore-formation 
process, as seen from the SEM image (
polysaccharide interface showed that fibers were encapsulated by the 
hydrogel remained separate 
and fibers generally maintained a parallel orientation within the 
 
Figure 3: SEM images of porous polysaccharide scaffold 
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5.2 Controlled release of BSA from polysaccharide scaffolds 
As SEM imaging had shown that fibers remain intact and were not significantly disrupted or 
diminished by the polysaccharide scaffold fabrication process, it was desired to see if the fibers 
could still maintain their controlled release properties as well. 
While successful controlled release of biologics, including BSA, from PEC fibers was well-
established by Liao et al., the release of biologics from a composite scaffold of polysaccharide gel 
and PEC fibers has not been investigated yet. It was thus desired to see if the composite scaffolds 
could serve as a controlled release platform for biologics, and how the composite scaffolds would 
affect the release profile compared to that of PEC fibers.  
The overall encapsulation efficiency, derived from subtracting BSA remaining in the residual 
solution after fiber drawing from total BSA incorporated in the initial drawing solution, was 
around 45%±0.97 (data not shown). It was shown in previous work by Liao et al. that rapid 
drawing (10 mm/s) of the PEC fibers resulted in a higher encapsulation efficiency compared to the 
slower drawing process (1 mm/s), due to the formation of beads along the fiber during rapid 
drawing. The faster the drawing speed, the larger the beads formed. It was thus suggested that the 
beads acted as bulk reservoirs of the biologic encapsulates, as the complexation process was 
hypothesized to occur imperfectly at the beads. This further explains the higher burst release 
experienced by rapidly drawn fibers as the bulk reservoir of BSA in the beads are released quicker 
than BSA in the beadless components. Given that beadless fibers would provide a better release 
profile than beaded fibers, even with lower encapsulation efficiency, the fabrication of beadless 
fibers was still preferentially used for this study. 
However, encapsulation efficiency was still lower than that reported by Liao et al., who presented 
a 60% encapsulation efficiency for beadless fibers. Technical problems could play a role, one 
notable effect being the inherent vibration of the speed-controlled motor. In their setup, the fiber-
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drawing rollers were attached by means of screws to the speed-controlled motor, creating a rigid 
fiber-drawing setup. As the smaller needle rollers used for fiber drawing were customized to fit the 
polysaccharide mould thereafter, they were too small to be screwed on and were instead attached 
by means of sticky tape to the rotational axis of the motor and projected outwards without further 
support. The motor vibrations were thus amplified at the ends of the needles upon which the fiber 
was drawn. The vibrations caused the drawn fiber to resonate vertically, repeatedly dipping the 
fiber in and out of the two polymer solutions at the interface. This caused a mixing at the interface 
of the two solutions, causing undesirable complexation to happen within the polymer solutions. 
This was further evident by the visible presence of white, coagulated residue left on the plate 
surface after fiber drawing was completed. Polymers that had electrolytically complexed within 
the drawing solutions could not be incorporated into the fiber, resulting in loss of polymer and 
BSA on the fiber drawing surface. Attempts to suppress the motor vibrations had improved the 
drawing efficiency, but the vibrations could not be completely eliminated, causing the lower 
encapsulation rate. 
Controlled release data for BSA from non-porous and porous polysaccharide scaffolds with fibers 
displayed a lower overall burst release compared to that of BSA released from fibers alone (Figure 
4). Moreover, the porous polysaccharide scaffold displayed a relatively steadier release profile 
over the course of 65 days compared to the non-porous polysaccharide scaffold. This could be 
explained by the structural differences in both non-porous and porous polysaccharide scaffolds. It 
is known that solute diffusion in a scaffold is largely determined by factors such as the tortuosity, 
connectivity and pore size of the scaffold network. In the non-porous scaffold, mass transport of 
BSA is limited by the relatively small pore size of the cross-linked polysaccharide network, 
compared to the porous scaffold where BSA is transported through larger macropores created by 
gas foaming from the reaction of sodium bicarbonate with acetic acid. Furthermore, the process of 
gas foaming resulted in highly-interconnected channels throughout the scaffold, facilitating the 
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outward diffusion of BSA through such channels.  As such, the release rate up to the 20-day 
timepoint was lower for the non-porous scaffold compared to the porous scaffold. However, a 
burst release from the non-porous scaffold at the 20 to 25 days interval showed that the release 
profile of the non-porous scaffold did not follow simple release kinetics. One possible reason was 
that the eventual degradation of the polysaccharide scaffold could have resulted in the burst release 
of BSA initially hindered by the polymer network. However, degradation studies of the scaffolds 
would have to be conducted to determine if this was indeed the cause of the burst release. 
Overall, BSA release rates from both composite scaffolds were lower than that of the fiber scaffold, 
as the presence of the polysaccharide mesh would have hindered solute transport by bulk flow. 
The total amount of BSA released between the three scaffolds was in the range of 41-44% over 65 
days, indicating that either a negligible quantity of BSA was degraded or lost during the additional 
polysaccharide encapsulation process of the fiber. 
  
 
Figure 4: Graph of cumulative BSA release over 65 days from (◆) non-porous scaffolds with fibers, 
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Overall, it was promising to note that the BSA encapsulated was not significantly lost during the 
process of encapsulating the BSA-loaded fiber in polysaccharide, nor in the process of 
effervescence in 20% acetic acid to create the porous gel, which were the key points of 
investigation before moving on to perform the controlled release with VEGF. 
5.3 Controlled release of VEGF from polysaccharide scaffolds 
As a steady state of VEGF release is preferred for angiogenesis, the porous polysaccharide-fiber 
scaffold was chosen for use in the subsequent controlled release experiment using VEGF. Heparin 
was incorporated into the fiber, as its high density of negatively charged sulfate groups has been 
noted to electrostatically bind to and stabilize the positively-charged VEGF, influencing  the 
growth factor release profile. The aim was thus to determine the optimal amount of alginate: 
heparin ratio for controlled release of VEGF. 
The initial encapsulation efficiencies during fiber drawing of all three configurations of alginate: 
heparin ratios were measure by ELISA. It was noted that, with an increasing concentration of 
heparin, the encapsulation efficiency improved significantly. 
Alginate: Heparin ratio 9:1 8:2 1:1 
Encapsulation efficiency 
(%) 
71.5±0.8 75.5±2.7 97±3.8 
 
Table 2: Encapsulation efficiency of VEGF expressed as a percentage of the total growth factor added 
to the chitosan drawing solution 
Notably, despite the good encapsulation efficiencies, the resultant total VEGF release quantity 
over 7 days was low, with an overall 5% of VEGF released by scaffolds with fibers of alginate: 
heparin ratios of 1:1 and 8:2 over 7 days, and only 3.2 % released by scaffolds of alginate: heparin 
ratios of 1:1. Furthermore, the cumulative release profile of scaffolds with fibers of an alginate: 
heparin ratio of 9:1 seemed to reach a plateau between 24 and 168 hours, during which negligible 
amounts of VEGF were released. 
One possible reason was that VEGF might have strong electrostatic interactions with 
groups in heparin, such that its release 
obtained by Liao et al. [80] for the encapsulation of PDGF
fibers. Their group had also reported a total released quantity of less than 5% from thei
based fibers over 25 days, compared to fibers without heparin where the release of PDGF
over 50% for the same time period. Hence, it can be extrapolated that VEGF might have remained 
bound within the fibers, especially so for fibers, with 
concentration of heparin incorporated.
Figure 5: Graph of VEGF release from porous polysaccharide
ratios of alginate: heparin, 9:1, 8:2, 1:1, 
In addition, the positively
surrounding negatively-charge
scaffold, slowing its diffusion out of t
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phosphate unit in the linkage. The mechanism of cross-linking with STMP can either yield a 
pyrophosphate cross-link formation between polymer chains, or a monophosphate crosslink 
formation. In the first case two negative charges are present on the linkage, whereas in the second, 
one negative charge is present on the linkage. Negative charges present on both phosphate and 
sulfate groups in the scaffold would thus be available to interact with VEGF. The hindered 
diffusion of VEGF  was also observed by our co-authors, who reported a significantly low overall 
release of VEGF from polysaccharide scaffolds similarly cross-linked with STMP and infused 
with a VEGF solution (publication in progress). Due to time limitations, the controlled release 
experiment was not continued beyond 7 days. 
 
5.4 Cell morphology studies of L929 cultured in polysaccharide scaffolds 
As a preliminary investigation, L929 mouse fibroblasts were used to assess the hydrogel-only and 
composite hydrogel-fiber scaffolds’ cell adhesion properties. L929 fibroblasts have been a popular 
cell model used in assessing cell behaviour and cytotoxicity of scaffolds for tissue engineering 
[84-86], as they are known to be relatively easy to culture, exhibit high cell adhesiveness to 
substrates and possess fast proliferation rates. Successful cell adhesion is a prerequisite of 
proliferation for anchorage-dependent cells [127]. Hence, a scaffold that is unfavourable to L929 
fibroblast growth can be generally acknowledged to have poor support for fibroblast proliferation.  
 
As the thick hydrogel scaffold posed imaging problems with regards to autofluorescence and light 
scattering , it was difficult to get a clear image of individual cells using fluorescence or light 
microscopy. Hence, SEM was opted as the imaging technique to observe cell behaviour within the 
scaffold. 
 
The seeded fibroblasts appeared dispersed throughout the volume of the scaffold. As the scaffold 
pore size was relatively large and the degree of interconnectivity between pores was high, cells 
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were able to access the bulk of the scaffold. Extended studies performed in our lab on L929 cell 
proliferation and viability in polysaccharide and polysaccharide-fiber composite scaffolds in a 
separate report [87] showed that fibroblasts in polysaccharide scaffolds remained viable and 
retained their proliferation capability, an indication that the polysaccharide hydrogel environment 
proved biocompatible and non-toxic to the cells. 
 
In polysaccharide scaffolds with no fibers, fibroblasts tend to remain mostly spherical and grouped 
in clusters, an indication that the polysaccharide surface was unfavourable for L929 fibroblast 
attachment. Although L929 cells seeded in polysaccharide scaffolds with fibers appeared to cluster 
around the fibers, they remained mostly in cell clusters as well, and individual L929 fibrolasts 
maintained a spherical morphology. In some instances, cells were observed to exhibit guided 
alignment along the fiber axis (Figure 6a), although in general, cells remained spherical and did 




Figure 6: SEM images of fibroblasts on (A) PEC fibers of the polysaccharide-fiber composite scaffold 
and (B) on the hydrogel surface of the polysaccharide-only scaffold 
 
It was previously reported that cells do not adhere well to surfaces of high hydrophilicity, 
preferring instead surfaces of moderate hydrophobicity [88,89], as a layer of water molecules 
adsorbed on the hydrophilic surface would prevent the adsorption of proteins that would otherwise 
50 µm 50 µm A B 
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mediate cell adhesion [90]. As the polysaccharide hydrogel was reported to possess a water 
content of over 90% [51], the surface hydrophilicity could have been a reason for the poor cell 
adhesion to the hydrogel surface. In addition, the net negative charge of the polysaccharide due to 
the phosphate groups incorporated from STMP during cross-linking might have further 
discouraged cell adhesion. As cell membranes have a net negative charge, cells have been known 
to be attracted, and hence preferentially attach, to positively-charged surfaces [91]. 
 
With respect to fibroblast attachment to the PEC fibers, the poor attachment might have been due 
to the absence of extracellular matrix proteins or adhesion molecules available for interaction with 
the cell adhesion surface receptors. In addition, the amine groups on deacetylated chitosan, which 
normally facilitate cell interaction and protein deposition on the chitosan surface due to their 
positive charge, are involved in electrostatic interactions with the negatively-charged hydroxyl 
groups of alginate, further decreasing the likelihood of cell adhesion to the fiber surface.  
 
As one of the common modes of failure of synthetic grafts is due to the formation of neo-intimal 
hyperplasia or stenosis, where there is undesired growth of fibroblasts or smooth muscle cells that 
cover the lumen of the graft [92], it is promising to see that the composite graft does not support 
the adherence of fibroblasts, which are amongst the cell types that express high adherence 








Results and Discussion - Fabrication and Characterization of PVA scaffold 
6.1 SEM images of patterned PVA films 
While patterning of PVA polymer by solvent-casting has been previously demonstrated [93], the 
patterned PVA films formed are not cross-linked and are highly unstable in water. Hence, their 
uses are limited to being convenient secondary moulds for pattern transfer from a master mould 
onto a non-water soluble substrate. The patterned PVA moulds are thus usually dissolved in water 
to release the non-soluble patterned substrate after its pattern replication from the PVA mould is 
complete. 
 
SEM images of the patterned PVA films by SEM showed that grating patterns were successfully 
replicated over the entire area of the polystyrene master moulds ( 
Figure 8). Unlike STMP-crosslinking of the polysaccharide, the amount of sodium hydroxide used 
for PVA cross-linking was nearly a fifth the concentration, hence cross-linking of PVA with 
STMP was hypothesized to be more strongly dependent on the solvent evaporation process.  
 
The fairly unique process of solvent-casting coupled with cross-linking employed was only 
possible due to the mechanism of cross-linking between PVA and STMP. The mechanism of 
STMP cross-linking was elaborated by Lack et al. [94] (Figure 7). Sodium hydroxide is first 
depleted in the reaction for PVA side chain activation and opening of the STMP ring. At the point 
when the reaction solution pH falls below 13, there is an accumulation of STPPg from the reaction 
between STMP and PVA, whereby the reaction does not proceed further. Due to both reactants 
STPPg and the activated hydroxyl side chain of PVA being negatively charged, it becomes quite 
difficult for nucleophilic substitution to take place, thus halting the initiation of cross-linking 
between PVA chains. However, upon evaporation, the concentration of the reagents and the 
alkalinity of the solution increases, allowing the reaction to continue. The negative charge and 
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repulsion on the α-phosphate is weaker compared to the other two phosphates in STPPg, making it 
more susceptible to nucleophilic attacks and allowing two PVA chains to be chemically cross-
linked by a phosphate bridge. As such, evaporation precedes the cross-linking reaction without 




Figure 7: The reaction mechanism of the cross-linking between PVA chains with STMP, as described 
by Lack et al. [94] 
It was noted previously that when the height of the PVA pre-cross-linked solutions in the mould 
were too high or when the solutions were left to evaporate too rapidly during the solvent-casting 
and cross-linking process, a persistent problem of hazing and blistering of the cast film surface 
was evident, covering most of the periphery of the pattern area. The area was typically 
characterized by a rough, bumpy surface with little or none of the intended pattern replicated. This 
was found to be a phenomenon of uneven drying throughout the thickness of the film coupled with 
the formation of vapour bubbles nucleating within the cast solvent [95,96]. A concentration 
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gradient of the polymer is created from the rapid surface evaporation, with the highest polymer 
concentration at the air-solution interface. The formation of a tight layer of polymer skin on the 
surface along with the increasing viscous thickening nearing the surface causes vapour bubbles 
formed in the bulk solution over time to meet with resistance when transporting out of the solvent 
by buoyancy or convective transport. Subsequently, the reduction of the pre-cross-linked solution 
depth in the mould as well as a retardation of evaporation processes was found to greatly improve 
the replication quality of the films, presumably by improving the uniformity of the evaporation 
process throughout the thickness of the solution during the solvent casting process. 
 
 
Figure 8: SEM images of patterned PVA films made from PS moulds of dimension aspects (A) 10 µm, 
(B) 2 µm and (C) 250 nm 
The films with grating patterns of 10 µm and 2 µm aspect ratio were additionally rehydrated and 
immersed in PBS, where the lateral swelling of the grating ridge and groove widths in solution 
was measured to be about 1.2 times as much as the dehydrated films. In addition, films were tested 
for stability by immersion in PBS for 7 days, after which they were observed under a bright-field 
microscope in solution. The grating dimensions remained unchanged, and patterns maintained 
their structural integrity ( 
Figure 9). This was a promising sign that cross-linked PVA films were able to sufficiently 
maintain their surface topography in physiological solution for prolonged periods of time. 
   50 5 µm 5 C A B 
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Figure 9: Bright-field images of PVA films in PBS made from PS moulds of (A) 10 µm and (B) 2 µm 
dimension aspect grating patterns after immersion in PBS for 7 days 
 
6.2 Surface characterization of PVA tubes with patterned lumen 
After it was established that PVA films could be patterned via solvent casting techniques, it was 
desired to see if the patterned film could be incorporated into a tube, an eventually as a vascular 
graft. Using glass rods as tubular moulds as previously described, intact tubes of 2 mm diameter 
could be made in this manner. However, grating patterns of prepared PVA tubes appeared 
diminished during the rolling and dipping process, as observed from SEM images of the 250 nm 
grating dimension sample. The poor pattern quality could be attributed to the method of annealing 
the rolled films by coating with PVA. During the initial vertical dipping of the wrapped film into a 
reservoir of PVA solution, fluid pressure and capillary action might have caused the PVA solution 
to travel up through the gap between the wrapped PVA film and the glass rod, causing loss of 
some pattern. 
 
Improvements to the dipping method have to be made in future to preserve the micro- or nano- 
topography of the solvent-casted patterns. For instance, the ends of the tube may be clamped or 
sealed with a hydrophobic plug, such as silicone glue, such that solution may not contact with the 
inner tube lumen during the dipping procedure. 
 
50 µm 50 µm A B 
However, it was generally observed that, compared to grafts produced by directly dipping and 
coating of the glass rod with PVA solution, the lumen of 
were macroscopically smoother in appearance (
undesired in vascular graft lumens, as the lumen roughness might likely cause turbulence and 
energy loss by friction in blood flow through
likelihood of thrombus formation, decreasing graft patency
Figure 10: SEM images of PVA tube cross
onto glass rods and (B) a close
film around glass rods followed by dipping, and (D) a close up of the lumen surface topography
 
6.3 Controlled release properties of
As the PVA tubes were prepared by a simultaneous evaporation and cross
chains within the tube scaffold were more tightly packed and possessed a
linking compared to the polysaccharide scaffold. 




grafts produced with wrapped PVA film 
Figure 10). Macroscopic roughness is generally 
 the graft after implantation. This in turn increases the 
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release properties could be investigated. Trypsin and BSA were chosen as model molecules for 
this experiment as their molecular weights were of similar order of magnitude to that of VEGF . In 
order to investigate the influence of charge on the molecule permeability, the molecules were also 
chosen on the basis that they expressed different charge polarities in physiological solution of pH 
7.4. 
It was observed that trypsin readily diffused across the PVA film, while the concentrations of BSA 
in both upper and lower chambers (Figure 1) remained relatively stable over the 48 hours, 
indicating no significant diffusion took place. Trypsin concentrations gradually equilibrated in 
both chambers over 48 hours, marked by a gradual decrease in the rate of change of trypsin 
quantity over time (Figure 11). 
At this point, it was postulated that the negatively charged phosphate groups in the cross-linked 
PVA film created a high electrostatic energy barrier for which the negatively-charged BSA could 
not cross. However, the positively-charged trypsin, which was also nearly three times smaller in 
molecular weight, appeared to cross the PVA film membrane more easily, as there was no 
surmounting energy barrier to overcome for the trypsin to approach and cross the PVA membrane. 
This was also in agreement to Shalviri et al.’s work on the permeability of negatively charged 
polysaccharide membranes to variously charged and sized molecules [98], where the group 
showed that molecules of opposite charge to the membrane had a nearly five-fold increase in 
permeability compared to molecules of similar molecular weight but possessing the same charge 




Figure 11: Graph of the concentrations of trypsin and BSA in the upper and lower chamber solutions 
taken during permeability assessment of the PVA membrane over time 
Trypsin was thus selected over BSA as the model molecule to use for controlled release studies of 
the PVA-fiber composite tubular scaffold. With the presence of a high density of negative charges 
from phosphate groups within the cross-linked PVA, it was a point of contention as to whether 
tubular PVA scaffolds could also serve as steady release reservoirs of positively-charged protein, 
and eventually VEGF, over time. The encapsulation efficiency of trypsin was measured to be 
88.0±0.8%, and thus the percentage released was normalized against the percentage of trypsin 
encapsulated.  
With the previous VEGF controlled release data previously obtained, the polyanion solution 
composed of an alginate: heparin ratio of 9:1 was used for the controlled release of trypsin. 
Figure 12: Graph of cumulative release of trypsin from PVA
tubular scaffolds over a period of 8 days
 
Controlled release experiments performed with the two scaffold types showed that PVA
tubes indeed displayed a prolonged release of trypsin over the experiment period of 8 days, despite 
the initial high burst release of over 45% (Figure 1
burst release rate than tubes composed of only PVA, the former having an initial burst release of 
less than half that of the latter in the first two hours. It could be inferred that the incorporation of 
PEC fibers into the PVA t
protein was regulated in its diffusion by both the polyanion to which it had interacted in the PEC 
fibers during polyelectrolyte complexation, and the negative charges present in the cro
PVA scaffold. 
6.4 Mechanical testing of PVA and PVA
While PVA is a relatively elastic material, PEC fibers have been known to be cha
stiff [99,100], thus one primary concern that the incorporation fibers could compromi
mechanical properties of the PVA
associated with short-term patency of
compliance compared to native tissue.
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influence of PEC fiber, including the effect of the orientation of the fibers within the scaffold, on 
the mechanical properties of the PVA-fiber composite. This could thus determine a suitable fiber 
orientation to use in the composite tubular graft. 
 
The elastic modulus of the composite Ec was measured from the tangential gradient of the graph 
segment between stress values of 0 to 49,050 N/m2, as this range corresponds to native stresses 
which the vessels are subjected to in the body [33]. Tensile test results (Figure 13A) showed that 
the elastic modulus for samples with parallel PVA fibers was 4.2 x 105 N/m2, greater than that of 
samples with perpendicular or no fibers, which was expected of composites under isostrain. In 
contrast, the PVA-fibers in perpendicular orientation, which were subjected to isostress, and the 
PVA samples were not significantly different from each other, and had approximate elastic moduli 
of 3.75 x 105 N/m2. 
 
The results obtained were in fact consistent with the known behaviour of anisotropic composites 
under stress. In the isostrain configuration of loading, the total load force experienced by the 
composite Fc is approximately the combined contribution of the PVA load force Fm and fiber load 
force Ff, as illustrated in equation (5.1), where  is stress of the respective components, and A is 
the cross-sectional area of the respective components, perpendicular to the direction of stretch. 
 





	  (5.2) 
 
  = 




In addition, the strain experienced by the composite and its components were the same, as they are 
stretched to the same degree, as outlined in equation (5.2). Given the general relationship between 
the stress, strain and elastic modulus of materials in equation (5.3), the resultant elastic modulus of 
the PVA-fiber composite under isostrain could be inferred from the abovementioned three 








  (5.4) 
 
In contrast, for fibers and PVA under isostress, an approximately equal amount of stress was 
transmitted across both fiber and PVA during tensile testing, while the total elongation of the 
composite was the sum of the elongation of the two components, as both components were 
positioned in series to the tensile force. This can be surmised by equations (5.5) and (5.6), where L 
is the component of the length parallel to the direction of applied force. Hence, the relationship for 
the Elastic moduli under isostress is given by the equation (5.7). 
 























Comparing the two relationships, the fiber, with its relatively high elastic modulus, contributed 
more significantly to the overall elastic modulus of the composite under isostrain conditions 
compared to isostress. In contrast, the stiffness of the fiber has a diminished influence when 
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orientated perpendicular to the direction of strain, resulting in no distinct difference in stiffness 
from the PVA-only samples.  
 
 





Figure 13: The (A) elastic modulus and (B) tensile strength of samples obtained from the tensile test 
experiment on PVA-only scaffold, PVA-fiber composite samples with fibers in perpendicular and 
parallel orientation. (*: p<0.1, **: p<0.05) 
 
Chandran et al. reported the average elastic modulus of arteries to be 4.55 x 105 N/m2 [101], which 
approximated closely to the measured elastic modulus of the PVA-fiber scaffold with fibers in 
parallel orientation. However, arterial elastic moduli have been shown to vary greatly under 
different conditions. For example, several groups had shown that carotid arteries become stiffer 
with age [34, 102]. The elastic modulus also varies with the artery anatomical location. For 




























































stiffness has been measured from the femoral artery, at 12 - 40 x 105 N/m2 [103]. As such, should 
the PVA-fiber composite be used as a graft, the elastic modulus of the graft can be varied by 
changing the ratio of fiber to PVA, as well as angle of fiber orientation to the graft axis. 
 
Fibers in parallel to the direction of strain were observed to fracture early at low strain, hence the 
short fiber fragments were thought to have limited contribution to the load bearing thereafter, 
while strength contribution from fibers orientated perpendicular to the direction of stress was 
thought to be low as well. However, the tensile strength of both composite sample types were 
observed to be higher than that of PVA samples with no fibers incorporated  (6.0 x 105 N/m2), and 
both composite stresses measured about 8.5 x 105 N/m2, regardless of the fiber orientation (Figure 
12B). Interfacial bonding between the PVA and fibers was one plausible explanation for the higher 
tensile strength in the composites [104,105], where the presence of electrostatic or Van der Waal’s 
forces of attraction between fibers and the surrounding PVA at their interface provided the transfer 
of load from the PVA to the fibers. Although the maximum tensile stress of all three sample 
configurations were still lower than that of native arteries, it is highly unlikely that such tensile 
stress values would be reached under physiological conditions [33,34], where the maximal active 
stress values of arteries were reported to be in the range of 1.5 x 105N/m2 [106,107]. 
 
6.5 Cell morphology studies of HUVEC cultured on PVA films 
As mentioned previously in chapter 3, PVA has generally been considered as an unfavourable 
material for cell adhesion due to its chemical structure, which contributes to its strongly 
hydrophilic nature. HUVEC cells seeded on PVA scaffolds of grating patterns with dimensions 2 
µm and 250 nm were observed to display greater cell density and number compared to the PVA 
control with no grating patterns. This was an indication that the influence of topography could not 
be ignored over surface chemistry, although current mechanisms of topography on cell behaviour 
remain unclear.  
 Between the two dimensions of gratings, 250 nm had a visibly higher number of cells attached 
compared to the 2 µm film samples. Moreover, cells appeared to be spread out more on the PVA 
films of dimensions 250 nm compared to the 
 
Figure 14: Fluorescent images of HUVEC cells seeded on patterned PVA scaffolds of grating pattern 
dimensions 2 µm, 250 nm and blank controls with no pattern. Cells were stained for their ac
filament structure with phalloidin
the images. 
 
One of the possible reasons could be the influence of topography on protein adsorption on the 
PVA surface, either of proteins from the m
cells during culture, specifically fibronectin for endothelial cells [124]
anchorage-dependent mammalian cells to a substrate surface follows the sequence of protein 
adsorption to the surface, cell
the initial step of protein adsorption is crucial for cell adhesion to a 
fibronectin, an oblate ellipsoid
that binds to integrins on the cell surface to promote cell adhesion, tends to adopt a more expanded, 
 
cells on films of dimensions 2 µm.
-TRITC. The direction of the gratings is indicated by the arrows in 
edium or ECM proteins synthesized and secreted 
. Generally, adhesion of 
-protein contact, followed by cell attachment and spreading
substrate surface.







 For example, 
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often linear configuration on flat, hydrophilic surfaces [108]. However, fibronectin better retains 
its native globular shape when adsorbed on surfaces with high curvatures, such as nanoparticles or 
ridges of the nano-scale range [109]. As such, binding sites of the fibronectin for cell attachment 
on the patterned substrate surface become available and thus could potentially improve cell 
attachment. However, such a hypothesis was not verified in this experiment, which could be done 
in future studies by checking the presence or distribution pattern of protein deposition on the 
gratings. 
 
Although endothelial cells did not appear to align in the direction of the gratings, studies by 
Uttayarat et al. [62] and Biela et al. [58] showed that endothelial cells also did not display 
significant elongation and alignment under static conditions, doing so only when the cell cultures 
were subjected to shear flow conditions. 
 
The cell study on patterned and non-patterned PVA films was fairly preliminary and no 
quantifiable data was obtained at this point of time. Nevertheless, it was still promising to note that 
there was a visual difference in cell behaviour towards the three different surface topographies of 
PVA, notably of which it seemed the presence of micro- and nano- grating topography appeared to 


















Due to the inherent problems associated with fabricating suitable small-diameter synthetic 
vascular grafts, a long-term solution has yet to be found for treatment of lower limb vascular 
diseases, many of which involve arteries of less than 6 mm in diameter. Two solutions proposed 
are the functionalization of the graft by incorporating a source of biomolecular cues to enhance 
vascular tissue regeneration and the endothelialisation of the graft lumen to maximise blood 
compatibility. In this study, two graft material candidates, PVA and pullulan-dextran 
polysaccharides, have been investigated to improve their functionality as bioactive scaffolds. The 
two materials had previously been investigated as vascular grafts in experiments. Although both 
types of materials were biocompatible and showed short-term patency, both materials were 
relatively inert, and did not contribute actively to tissue regeneration processes. 
 
From the controlled release experiments, it has been demonstrated that the combination of PEC 
fibers with PVA or polysaccharide scaffolds improved the resulting composite scaffolds’ ability to 
produce a sustained release of proteins. With regards to the polysaccharide-fiber composite 
scaffold, a sustained release of BSA and VEGF was observed, with the composite scaffold 
exhibiting a relatively lower burst release compared to the release from PEC fibers only.  
 
The PVA scaffold was shown in this study to be impermeable to the negatively charged protein 
BSA, but permeable to the positively-charged protein Trypsin, due to the scaffold’s high polymer 
density due to the solvent casting process. PVA-fiber composite scaffold showed a sustained 
release of Trypsin and a relatively lower burst release compared to the release profile of the PVA-
only scaffold, demonstrating that the incorporation of PEC fibers had improved the sustained 




This study has also demonstrated that a simultaneous solvent-casting and cross-linking fabrication 
method can be used for the production of patterned PVA films, with the patterns being 
successfully retained when immersed in physiological solution. This method of pattern production 
is an advantage over other current methods such as electron beam lithography, polymer demixing 
and chemical etching [61], as the method allows the replication patterns on the micro- and nano-
scale, with the ability to replicate large surface areas of the pattern simultaneously. Furthermore, 
no organic solvent is employed, eliminating the possibility of cytotoxic effects that may be caused 
by residual solvents. With the current method of producing small-diameter PVA tubes with 
patterned lumens, the surface macro-structure can be controlled.  
 
Endothelial cell adhesion studies on micro- and nano-patterned PVA films, fabricated using the 
abovementioned method, have also shown improved endothelial cell adhesion of HUVECs on 
patterned surfaces compared to non-patterned PVA surfaces. In particular, of the two grating 
dimension patterns, surfaces of PVA films with gratings of dimensions 250 nm appeared to 
demonstrate better cell adhesion than that on gratings of dimensions 2 µm. The demonstration of 
improvement of endothelial cell adhesion to patterned PVA surfaces is a promising result that 
could lead to the use of patterned surfaces in PVA vascular graft lumens to enhance endothelial 
cell adhesion. 
 
Fibroblast cell adhesion studies conducted on the polysaccharide-PEC scaffold showed two 
different types of cell behaviour on each scaffold component. Fibroblast cells on the 
polysaccharide surface assumed a spherical morphology with poor cell adhesion. This was 
favourable as a graft material surface with low fibroblast adhesion tends to discourage intimal 
hyperplasia or stenosis formation within the graft lumen. On the other hand, although cell 
adhesion to the embedded fibers was also poor, cells appeared to align to the long axis of the fibers, 




The effect of the incorporation of PEC fibers on the overall mechanical properties of PVA-fiber 
composites was also investigated in this study. It was shown that the incorporation of fibers not 
only improved the elastic modulus of the PVA-fiber scaffold over the PVA-only scaffold, but also 















































Both scaffolds have the advantage of being fabricated completely in aqueous solutions at 
physiological temperatures. As no high temperature treatment and organic solvents were involved 
in the fabrication processes, biological molecules such as growth factors could be incorporated 
into the scaffold during the fabrication process. This was successfully demonstrated in the 
controlled release experiments performed, with the results as described above. 
 
An advantage of such a method of protein incorporation within PEC fibers during the scaffold 
fabrication process is the ability to control the spatial distribution within the scaffold of the protein 
encapsulated. For example, endothelial cells are known to be chemotactic, showing propensity to 
migrate in the direction of increasing concentrations of VEGF [110]. It has been of general interest 
to develop a tubular graft that can produce a gradient of growth factor to direct and promote 
endothelial cell growth in vascular grafts [111], which can be achieved by localizing fibers 
encapsulating VEGF towards the middle of the scaffold during graft fabrication. In this manner, a 
bi-directional gradient of VEGF can be established as VEGF is continuously released by the fiber 
and diffuses along the length of the tube. As endothelialisation of implanted vascular grafts is 
often a slow and incomplete process, graft materials are left exposed to blood flow for prolonged 
periods of time and are susceptible to thrombogenicity. A gradient of growth factor in the graft 
could thus shorten the time required for re-endothelialisation, improving graft patency.  
 
However, further studies have to be carried out in characterizing the scaffolds as sustained release 
reservoirs for growth factors. In the case of the polysaccharide-fiber scaffold, a controlled and 
sustained release of BSA from the polysaccharide-fiber scaffold has been shown. While controlled 
release of VEGF from the scaffold has been demonstrated, a longer period of assessment should 
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be done in order to obtain a more comprehensive release profile of VEGF from the polysaccharide 
scaffold.  
 
In addition, although the released growth factor can be detected by ELISA indicating that the 
VEGF peptide is likely still intact, additional bioactivity studies of the released VEGF have to be 
performed to ensure that both encapsulated and released VEGF have not denatured and still retain 
their bioactivity. The bioactivity of VEGF could be evaluated in vitro by determining the 
proliferative capacity of an endothelial cell line after VEGF treatment.  For VEGF released in 
solution, supernatant of the release solution could be collected and incubated with an in vitro 
culture of endothelial cells. VEGF retained within the PEC fiber could be obtained in solution by 
extracting the PEC fiber from the gel and performing a digestion of the fiber using chitosanase and 
alginase. Incubation of cells with medium containing a prepared concentration of VEGF and 
medium without VEGF would serve as positive and negative experiment controls respectively. 
Cell proliferation could be quantified at the end of the incubation period by performing by cell 
count using a haemocytometer. By quantifying the proliferation rates of in-vitro HUVEC cultures, 
the rate of proliferation would serve as an indicator to whether VEGF, both in solution and within 
the PEC fiber, still remains bioactive. 
 
While permeability and controlled release experiments with trypsin as the model molecule have 
shown that PVA tubular scaffolds can act as controlled release reservoirs as well, trypsin has been 
found to possess autolytic activities [112], thus altering the molecular weight of the enzyme by 
introducing peptide fragments and rendering the permeability experiment inaccurate in terms of 
determining the molecular weight of protein that may pass through the PVA membrane. It is thus 
necessary to repeat the experiments with an alternative protein that is stable under such 
experimental conditions. Positively charged proteins such as lysozyme, cationic trypsinogen and 
cytochrome C [113,114] can be considered as model proteins in place of VEGF to assess 
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permeability and controlled release properties, which would otherwise be too costly to be used in 
such preliminary experiments. Eventually, after the controlled release capability of the PVA-fiber 
tubular graft has been ascertained, release properties of the graft with VEGF may be carried out. 
 
 
Cell adhesion studies on the polysaccharide-fiber scaffold, particularly on the observed contact 
guidance of fibroblasts by the PEC fibers in the scaffold, could be further investigated. PEC fibers 
could potentially be used to guide the growth of cells and hence regeneration of tissue within the 
vascular graft. In particular, fibers could potentially guide the growth and alignment of smooth 
muscle cells in the graft, providing a possible approach to regenerating the tunica media of the 
artery. Smooth muscle cells are typically arranged in a concentric, helical manner within the vessel 
tunica media [116]. and the structure and alignment of smooth muscles cells in native vessels are 
crucial in providing active tension in muscle contraction, as well as increasing circumferential 
stiffness to resist distension [117]. 
 
ECM proteins may be incorporated into PEC fibers to improve their cell adhesion properties, an 
application that could be investigated in future studies. In a recently published study on liver tissue 
regeneration by Tai et al., hepatocytes were successfully cultured on PEC fibers incorporated with 
various ECM molecules native to liver tissue [115], showing the possibility of modulating cell 
adhesion properties of PEC fibers with this method. Further studies can be performed to assess the 
improvement of smooth muscle cell adhesion to PEC fibers incorporated with native extracellular 
matrix proteins such as elastin. Fibers may be embedded in a continuously drawn, helical manner 
around the tubular graft to mimic the orientation of smooth muscle cells within native vessels. By 
controlling the orientation of the fibers within the scaffold and type of ECM molecules 






Endothelial cell adhesion experiments performed on the patterned PVA films will have to be 
repeated for consistency, and quantification of the proliferation as well as cell spreading can be 
performed to provide a clearer perspective on the degree of influence the patterned films have on 
the cells. In addition, protein deposition assays could be done to verify the hypothesis that there 
was preferential adsorption of proteins to curvatures on the nano- or micr-gratings, that resulted in 
better cell adhesion to the gratings. This could be carried out by incubating FITC-conjugated 
fibronectin with PVA films, and thereafter observing the protein distribution pattern under 
fluorescence microscopy. As HUVECs have been known to secrete fibronectin in culture [124], 
cell-seeded PVA films could be de-cellularized after a period of culture, and the films with the 
remaining protein deposited can be immunostained for fibronectin, which can then be visualized 
by fluorescence microscopy. 
 
As studies by Uttayarat et al. [62] and Biela et al. [58] have shown, cells are more likely to exhibit 
alignment and migration tendencies under native vessel flow conditions. Hence, patterned tubes 
seeded with endothelial cells in their lumen can be subjected to flow conditions using a bioreactor, 
and thereafter assessed for endothelial cell alignment against cell-seeded tubes cultured under 
static conditions. Migration of endothelial cells would be better assessed with real-time imaging of 
the cultures on patterned PVA films, using a heated flow chamber mounted on a microscope stage, 
as tubular scaffolds are opaque and would pose problems should real-time viewing of the cultures 
in the patterned lumen be desired. 
 
Further to the improved mechanical properties observed in the PVA-fiber scaffold, additional 
studies on the moderation of the fiber-to-PVA ratio as well as fiber orientation within the scaffold 
could be done to expand the indications of the PVA-fiber scaffold to different anatomical sites and 




Another important mechanical property to consider is the compliance of the graft, which is defined 
as the degree of distension of the vessel or graft in response to changes in blood pressure [118], 
and should match closely to that of the host artery. To investigate vessel compliance, a mechanical 
setup comprising of a pressure gauge fitted on one end of the graft to be measured and an injector 
system secured to the other can be utilised. By taking measurements of the graft volume expansion 
between 120 mmHg and 80 mmHg, which are the systolic and diastolic pressures experienced by 
native arteries, the compliance of the graft can be assessed [119]. 
 
Finally, implanted grafts would inevitably undergo a multitude of interactions in a complex 
physiological environment, including interactions with blood serum proteins, inflammatory 
cytokines [120] and a variety of tissue and cell types. As in-vitro experiments can only provide 
limited information on how the grafts might perform after implantation, in-vivo experiments will 
ultimately have to be carried out on grafts. Information that can be obtained would be the degree 
of tissue regeneration the graft can support, namely the induction of spontaneous 
endothelialisation, or migration and alignment of smooth muscle cells. Patency of grafts can also 
be assessed, by looking into the susceptibility of the graft lumen to thrombogenesis, or presence of 
anastomotic aneurysm formation due to vessel fatigue at the anastomosis sites [121]. 
 
Although the results presented here are preliminary and further studies have yet to be done to 
create a more detailed and defined characterization of the scaffolds as vascular grafts, PVA and 
polysaccharide scaffolds in this study have shown promise as candidates for vascular graft tissue 
regeneration, in terms of their ability to perform controlled release of biologics, as well as the 
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